Objective:

To determine whether treatment response in rheumatoid arthritis (RA) depends on joint location following the initiation of biologic or targeted synthetic disease-modifying antirheumatic drugs.

Approach:

• Primary Analysis: Included 598 bio-naive RA patients initiating a TNF inhibitor with at least one swollen joint.
• Secondary Analyses: Included 1,942 patients initiating various treatments regardless of previous biologic exposure, followed for up to 2 years.

Key Findings:

• Wrist and second and third metacarpophalangeal joints showed slower resolution of swelling compared to other joints.
• Most joints resolved swelling within the first 6 to 12 months, with recurrent synovitis most common in specific joints.
• No statistically significant differences in joint-specific responses between treatment classes in bio-naive patients.

Interpretation:

The slower improvement in certain joints is associated with joint location rather than specific treatment agents.

Limitations:

• Observational design did not support causal inference.
• Synovitis assessed clinically without imaging confirmation.
• Excluded patients who discontinued treatment before joint swelling resolved.

Conclusion:

Physicians may need to evaluate treatment response later when the wrist or second and third metacarpophalangeal joints are involved.

Sources:

• RMD Open